Live data · NADAC + Part D CY24 · reviewed daily

Paclitaxel Protein-Bound Particles

Microtubule Inhibitor class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2025-04-15
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
—/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
—
Across all dosage forms in distribution.
Highest NADAC
—
Range is tight.
Plans with PA
0 / 329
Zero PA friction across surveyed plans.

Questions a plan sponsor actually asks.

FAQPage schema6 entries indexed · 4 visible
What is Paclitaxel Protein-Bound Particles used for?

Paclitaxel Protein-Bound Particles is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Paclitaxel Protein-Bound Particles?

No. Paclitaxel Protein-Bound Particles is brand-only with no generic equivalents currently in market.

How much does my plan pay for Paclitaxel Protein-Bound Particles?

NADAC pricing data not currently available for this drug.

Is Paclitaxel Protein-Bound Particles on the FDA shortage list?

No. Paclitaxel Protein-Bound Particles is not currently on the FDA Drug Shortage Database.

2 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.